GlassScriptPhysician profile
Jonathan B Dixon
NPI 1609840073
$802.44
in general payments reported to CMS, 2019-2025
16 companies · $65.60 in 2025
The $65.60 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $31.13 · 2021: $106 · 2023: $178 · 2024: $141 · 2025: $65.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $384.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $205.25 | 2021-2024 | Vraylar |
| Novartis Pharmaceuticals Corporation | $100.24 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $84.25 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $66.17 | 2019 | |
| Novo Nordisk INC | $52.69 | 2019-2021 | |
| Esperion Therapeutics, INC. | $50.34 | 2021 | |
| Pfizer INC. | $41.77 | 2019-2025 | |
| Amgen INC. | $38.63 | 2019 | |
| Axsome Therapeutics, INC. | $34.50 | 2025 | Auvelity |
| Lilly USA, LLC | $28.13 | 2024 | Zepbound, Mounjaro |
| Shield Therapeutics INC | $22.68 | 2023 | Accrufer |
| Xeris Pharmaceuticals, INC. | $22.60 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.31 | 2021 | |
| Cipher Pharmaceuticals US LLC | $13.63 | 2025 | Natroba, Spinosad |
| Glaxosmithkline, LLC. | $13.18 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Dixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.